Talquetamab Consolidation After BCMA CAR-T
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 17 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, GPRC5D, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1778
- NCT Identifier
- NCT06066346
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.